Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diabetes

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 91 articles:
HTML format
Text format



Single Articles


    June 2019
  1. HUSAIN M, Birkenfeld AL, Donsmark M, Dungan K, et al
    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2019 Jun 11. doi: 10.1056/NEJMoa1901118.
    PubMed     Text format     Abstract available


  2. HEROLD KC, Bundy BN, Long SA, Bluestone JA, et al
    An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMoa1902226.
    PubMed     Text format     Abstract available


  3. ROSEN CJ, Ingelfinger JR
    Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention.
    N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMe1907458.
    PubMed     Text format    


  4. PITTAS AG, Dawson-Hughes B, Sheehan P, Ware JH, et al
    Vitamin D Supplementation and Prevention of Type 2 Diabetes.
    N Engl J Med. 2019 Jun 7. doi: 10.1056/NEJMoa1900906.
    PubMed     Text format     Abstract available


  5. WEXLER DJ
    D2d - No Defense against Diabetes.
    N Engl J Med. 2019 Jun 7. doi: 10.1056/NEJMe1906815.
    PubMed     Text format    


  6. LIPSKA KJ, Laiteerapong N
    Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial.
    N Engl J Med. 2019;380:2266-2267.
    PubMed     Text format    


  7. REAVEN PD, Emanuele NV, Wiitala WL, Bahn GD, et al
    Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
    N Engl J Med. 2019;380:2215-2224.
    PubMed     Text format     Abstract available


    May 2019
  8. INGE TH, Courcoulas AP, Jenkins TM, Michalsky MP, et al
    Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults.
    N Engl J Med. 2019;380:2136-2145.
    PubMed     Text format     Abstract available


  9. WIVIOTT SD, Raz I, Sabatine MS
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2019;380:1881-1882.
    PubMed     Text format    


  10. AKINCI B
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;380:1881.
    PubMed     Text format    


  11. BAGLIONI P
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;380:1880-1881.
    PubMed     Text format    


    April 2019
  12. TAMBORLANE WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, et al
    Liraglutide in Children and Adolescents with Type 2 Diabetes.
    N Engl J Med. 2019 Apr 28. doi: 10.1056/NEJMoa1903822.
    PubMed     Text format     Abstract available


  13. ROGERS KK
    Diabetes and Disclosure.
    N Engl J Med. 2019;380:1495-1497.
    PubMed     Text format    


  14. INGELFINGER JR, Rosen CJ
    Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.
    N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMe1904740.
    PubMed     Text format    


  15. PERKOVIC V, Jardine MJ, Neal B, Bompoint S, et al
    Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744.
    PubMed     Text format     Abstract available


    March 2019
  16. FERENCE BA, Ray KK, Catapano AL, Ference TB, et al
    Mendelian Randomization Study of ACLY and Cardiovascular Disease.
    N Engl J Med. 2019;380:1033-1042.
    PubMed     Text format     Abstract available


    February 2019
  17. RIDKER PM, Everett BM, Pradhan A, MacFadyen JG, et al
    Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    N Engl J Med. 2019;380:752-762.
    PubMed     Text format     Abstract available


    January 2019
  18. KARANDINOS G, Bourgois P
    The Structural Violence of Hyperincarceration - A 44-Year-Old Man with Back Pain.
    N Engl J Med. 2019;380:205-209.
    PubMed     Text format    


    December 2018
  19. RAWSHANI A, Rawshani A, Gudbjornsdottir S
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2575.
    PubMed     Text format    


  20. HU Y, Hu FB, Sun Q
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2574-2575.
    PubMed     Text format    


  21. KANNT A
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2574.
    PubMed     Text format    


  22. MANSI IA
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2573-2574.
    PubMed     Text format    


  23. FAN T, Yang S, Geng Q
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2573.
    PubMed     Text format    


  24. ANKER MS, Kalantar-Zadeh K, Doehner W
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2572-2573.
    PubMed     Text format    



  25. Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2572-2575.
    PubMed     Text format    


    November 2018
  26. MORA CARPIO AL, Stempel JM
    Pneumococcal Bacteremia and Meningitis.
    N Engl J Med. 2018;379:2063.
    PubMed     Text format    


  27. MARCHAND L
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970.
    PubMed     Text format    


  28. LAL A, Katta SR, Trivedi N
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970.
    PubMed     Text format    


  29. BALLY L, Thabit H, Hovorka R
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970-1971.
    PubMed     Text format    


  30. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389.
    PubMed     Text format     Abstract available


  31. MEKAHLI D, Jouret F
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784-5.
    PubMed     Text format    


  32. ROBERTSON GL
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784.
    PubMed     Text format    


  33. SPITAL A
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784.
    PubMed     Text format    



  34. Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784-1786.
    PubMed     Text format    


  35. DOWNING NS, McMullan CJ, Rennke HG, Levy BD, et al
    Complements from the Lung.
    N Engl J Med. 2018;379:1767-1773.
    PubMed     Text format    


    September 2018

  36. Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-1184.
    PubMed     Text format    


  37. RUSSELL MJ, Kanthimathinathan HK
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1183.
    PubMed     Text format    


  38. WHITE PC
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1182-3.
    PubMed     Text format    


  39. KAMEL KS, Carlotti APCP, Halperin ML
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-2.
    PubMed     Text format    


    August 2018

  40. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804989.
    PubMed     Text format     Abstract available



  41. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988.
    PubMed     Text format     Abstract available


  42. BOHULA EA, Wiviott SD, McGuire DK, Inzucchi SE, et al
    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1808721.
    PubMed     Text format     Abstract available


  43. TRIPATHY K
    Asteroid Hyalosis.
    N Engl J Med. 2018;379:e12.
    PubMed     Text format    


  44. SCHROEDER SA
    Heavier but Healthier - Diabetes and Smoking Cessation.
    N Engl J Med. 2018;379:684-685.
    PubMed     Text format    


  45. HU Y, Zong G, Liu G, Wang M, et al
    Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality.
    N Engl J Med. 2018;379:623-632.
    PubMed     Text format     Abstract available


  46. RAWSHANI A, Rawshani A, Franzen S, Sattar N, et al
    Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2018;379:633-644.
    PubMed     Text format     Abstract available


  47. BALLY L, Thabit H, Hartnell S, Andereggen E, et al
    Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:547-556.
    PubMed     Text format     Abstract available


  48. FENSKE W, Refardt J, Chifu I, Schnyder I, et al
    A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:428-439.
    PubMed     Text format     Abstract available


  49. ROSEN CJ, Ingelfinger JR
    A Reliable Diagnostic Test for Hypotonic Polyuria.
    N Engl J Med. 2018;379:483-484.
    PubMed     Text format    


    June 2018
  50. CAN B, Can B
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed     Text format    


  51. CADWELL JB, Shukla AP
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed     Text format    



  52. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537-2538.
    PubMed     Text format    


  53. SPERLING MA
    Fluid Composition, Infusion Rate, and Brain Injury in Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2336-2338.
    PubMed     Text format    


  54. KUPPERMANN N, Ghetti S, Schunk JE, Stoner MJ, et al
    Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2275-2287.
    PubMed     Text format     Abstract available


    April 2018
  55. BJERREGAARD LG, Jensen BW, Angquist L, Osler M, et al
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:1302-1312.
    PubMed     Text format     Abstract available


    March 2018
  56. HUSEBYE ES, Anderson MS, Kampe O
    Autoimmune Polyendocrine Syndromes.
    N Engl J Med. 2018;378:1132-1141.
    PubMed     Text format    


  57. PAWAR AS, Kattah AG
    Lithium-Induced Nephropathy.
    N Engl J Med. 2018;378:1042.
    PubMed     Text format    


  58. KHOO TK, Olson KM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


  59. DOUMAS M, Imprialos KP, Stavropoulos K
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


  60. CONTE C, Secchi A, Napoli N
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    


  61. GOGTAY NJ, Bose D, Thatte UM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    



  62. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966-968.
    PubMed     Text format    


    February 2018
  63. FLYNN JT
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:580.
    PubMed     Text format    


  64. MEI ZB, Xiao Y
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed     Text format    


  65. JONNALAGADDA VG, Metety VK
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed     Text format    



  66. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579-581.
    PubMed     Text format    


    January 2018
  67. AGARWAL A
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:302.
    PubMed     Text format    


  68. CEREDA E
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301-2.
    PubMed     Text format    


  69. DI BELLA S, Monticelli J, Luzzati R
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301.
    PubMed     Text format    


    December 2017
  70. IMPRIALOS KP, Stavropoulos K, Doumas M
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed     Text format    


  71. HOLMAN RR, Bethel MA, Hernandez AF
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed     Text format    


    November 2017
  72. THORNTON SN, Regnault V, Lacolley P
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196-7.
    PubMed     Text format    


  73. IMPRIALOS KP, Stavropoulos K, Doumas M
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196.
    PubMed     Text format    


  74. GULLI G
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-6.
    PubMed     Text format    


  75. TONNEIJCK L, van Raalte DH, Muskiet MHA
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195.
    PubMed     Text format    



  76. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-2199.
    PubMed     Text format    


  77. DE BOER IH
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2198.
    PubMed     Text format    



  78. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-2099.
    PubMed     Text format    


  79. RAJAGOPALAN S, Brook R
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098-9.
    PubMed     Text format    


  80. FERNANDEZBALSELLS MM, Sojo-Vega L, Ricart-Engel W
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098.
    PubMed     Text format    


  81. BAGLIONI P
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-8.
    PubMed     Text format    


  82. PERFETTI R
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995.
    PubMed     Text format    


  83. TAYEK JA, Danese PNN, Smith MS
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994-5.
    PubMed     Text format    


  84. OGUNSAKIN AA, Jain N, Dagogo-Jack S
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994.
    PubMed     Text format    



  85. Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995-1996.
    PubMed     Text format    


  86. MARCOVECCHIO ML, Chiesa ST, Bond S, Daneman D, et al
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2017;377:1733-1745.
    PubMed     Text format     Abstract available


    October 2017
  87. MATSUO T, Ishii N
    Acute Esophageal Necrosis.
    N Engl J Med. 2017;377:1378.
    PubMed     Text format    


    September 2017
  88. ADAMS TD, Davidson LE, Litwin SE, Kim J, et al
    Weight and Metabolic Outcomes 12 Years after Gastric Bypass.
    N Engl J Med. 2017;377:1143-1155.
    PubMed     Text format     Abstract available


  89. HOLMAN RR, Bethel MA, Mentz RJ, Thompson VP, et al
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017 Sep 14. doi: 10.1056/NEJMoa1612917.
    PubMed     Text format     Abstract available


  90. GARG SK, Henry RR, Banks P, Buse JB, et al
    Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMoa1708337.
    PubMed     Text format     Abstract available


  91. NATHAN DM
    Adjunctive Treatments for Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMe1711296.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: